CareDx Inc. logo

CareDx Inc. (CDNA)

Market Closed
16 Oct, 08:00 PM
NASDAQ (NMS) NASDAQ (NMS)
$
64. 00
-2.67
-4.012%
$
3.22B Market Cap
- P/E Ratio
- Div Yield
1.5M Volume
-0.74 Eps
$ 66.67
Previous Close
Add Transaction
Day Range
62.85 68.09
Year Range
14.03 72.51
Want to track CDNA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
CareDx Inc (CDNA) Trading 6.16% Higher on Oct 2

CareDx Inc (CDNA) Trading 6.16% Higher on Oct 2

Shares of CareDx Inc (CDNA, Financial) surged 6.16% in mid-day trading on Oct 2. The stock reached an intraday high of $32.97, before settling at $32.83, up from its previous close of $30.93.

Gurufocus | 2 years ago
CAREDX INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA

CAREDX INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA

NEW ORLEANS, LA / ACCESSWIRE / September 30, 2024 / Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq.

Accesswire | 2 years ago
CareDx Resolves Key Issues: Poised For Growth In Transplant Diagnostics

CareDx Resolves Key Issues: Poised For Growth In Transplant Diagnostics

CDNA has resolved corporate instability and insurance issues, showing potential for sustainable growth with innovative transplant testing services like AlloSure, AlloMap, and HeartCare. CDNA's products are supported by scientific literature and recent Medicare coverage expansions, enhancing their market potential and revenue growth prospects. The appointment of CEO John W. Hanna provides stable leadership and strategic direction for long-term objectives.

Seekingalpha | 2 years ago
CareDx, Inc. (CDNA) Hit a 52 Week High, Can the Run Continue?

CareDx, Inc. (CDNA) Hit a 52 Week High, Can the Run Continue?

CareDx (CDNA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks | 2 years ago
CareDx (CDNA) Upgraded to Strong Buy: What Does It Mean for the Stock?

CareDx (CDNA) Upgraded to Strong Buy: What Does It Mean for the Stock?

CareDx (CDNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks | 2 years ago
Compared to Estimates, CareDx (CDNA) Q2 Earnings: A Look at Key Metrics

Compared to Estimates, CareDx (CDNA) Q2 Earnings: A Look at Key Metrics

The headline numbers for CareDx (CDNA) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks | 2 years ago
CareDx, Inc. (CDNA) Q2 2024 Earnings Call Transcript

CareDx, Inc. (CDNA) Q2 2024 Earnings Call Transcript

CareDx, Inc. (NASDAQ:CDNA ) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Greg Chodaczek - Managing Director John Hanna - President and CEO Abhishek Jain - Chief Financial Officer Robert Woodward - Chief Scientific Officer Alex Johnson - President, Patient and Testing Services Conference Call Participants Bill Bonello - Craig-Hallum Kayla Hostetler - Jefferies Prashant Kota - Goldman Sachs Andrew Cooper - Raymond James Nathan Kariko - Stephens Vivian Bais - BTIG Yi Chen - H.C. Wainwright Thomas DeBourcy - Nephron Research Operator Good day, everyone.

Seekingalpha | 2 years ago
CareDx (CDNA) Q2 Earnings and Revenues Beat Estimates

CareDx (CDNA) Q2 Earnings and Revenues Beat Estimates

CareDx (CDNA) came out with quarterly earnings of $0.25 per share, beating the Zacks Consensus Estimate of a loss of $0.13 per share. This compares to loss of $0.18 per share a year ago.

Zacks | 2 years ago